CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology
company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman,
President, and Chief Executive Officer, will present corporate overview presentations at the 16th Annual Needham
Healthcare Conference at the Westin New York Grand Central and the 24th Annual BioCentury Future Leaders In the Biotech
Industry Conference at the Millennium Broadway Hotel in New York City. Presentation details for both conferences are summarized
below.
The presentation at the 16th Annual Needham Healthcare Conference will be webcast live and may be
accessed on the Investors page of the company’s website at www.investors.leaptx.com, where a replay of the event will also be available for a limited
time.
Leap Presentation Details:
16th Annual Needham Healthcare Conference
Date: April 5, 2017
Time: 3:00 P.M. Eastern Time
24th Future Leaders in the Biotech Industry Conference
Date: April 7, 2017
Time: 9:30 A.M. Eastern Time
About Leap Therapeutics
Leap Therapeutics’ (NASDAQ:LPTX) most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the
Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with gastroesophageal cancer in combination with paclitaxel and
in patients with biliary tract cancers in combination with gemcitabine and cisplatin. DKN-01 has demonstrated single agent activity
in non-small cell lung cancer patients. Leap’s second clinical candidate, TRX518, is a novel, humanized GITR agonist monoclonal
antibody designed to enhance the immune system’s anti-tumor response. For more information about Leap Therapeutics, visit
http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at
http://www.sec.gov or via http://www.investors.leaptx.com/.
FORWARD LOOKING STATEMENTS
Some of the statements in this release are forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of
1995, which involve risks and uncertainties. These statements relate to future events of Leap’s development of DKN-01, TRX518, and
other programs, future expectations, plans and prospects. Although Leap believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements. Leap has attempted to identify forward looking statements by
terminology including ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘projects,’’ ‘‘intends,’’
‘‘potential,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘approximately’’ or other words that convey uncertainty of
future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and
unknown risks, uncertainties, and other factors. Any forward looking statements contained in this release speak only as of its
date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT Douglas E. Onsi Chief Financial Officer Leap Therapeutics, Inc. donsi@leaptx.com 617-714-0360 Argot Partners Susan Kim 212-203-4433 susan@argotpartners.com or Heather Savelle 617-663-4863 heather@argotpartners.com
